MacroGenics | MGNX

Stock Price
2.00
Daily Change
0.06 3.09%
Monthly
24.22%
Yearly
-38.46%
Q3 Forecast
1.98

Peers Price Chg Day Year Date
Daiichi Sankyo 3,621.00 5.00 0.14% -35.87% Sep/05
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Geron 1.40 0.02 1.45% -67.06% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Xencor 8.55 0.18 2.15% -47.16% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

MacroGenics traded at $2.00 this Friday September 5th, increasing $0.06 or 3.09 percent since the previous trading session. Looking back, over the last four weeks, MacroGenics gained 24.22 percent. Over the last 12 months, its price fell by 38.46 percent. Looking ahead, we forecast MacroGenics to be priced at 1.98 by the end of this quarter and at 1.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.